http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 12 Mar 2026 08:36:42 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Earnings/Precision+BioSciences+%28DTIL%29+Tops+Q4+EPS+by+105c/26149974.html <p>Precision BioSciences (NASDAQ: DTIL) reported Q4 EPS of $1.05. Revenue for the quarter came in at $34 million.</p><p>For earnings history and earnings-related data on Precision BioSciences (DTIL) <a href="http://www.streetinsider.com/ec_earnings.php?q=DTIL">click here</a>.</p> http://www.streetinsider.com/Earnings/Precision+BioSciences+%28DTIL%29+Tops+Q4+EPS+by+105c/26149974.html Thu, 12 Mar 2026 08:36:42 -0400 DTIL http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++PRECISION+BIOSCIENCES+++++For%3A+Dec+31/26149331.html si-local-file:///var/storage/secattach/20260312/26149331.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++PRECISION+BIOSCIENCES+++++For%3A+Dec+31/26149331.html Thu, 12 Mar 2026 07:32:00 -0400 DTIL O.20406057 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++PRECISION+BIOSCIENCES+++++For%3A+Dec+31/26149331.html si-local-file:///var/storage/secattach/20260312/26149331.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++PRECISION+BIOSCIENCES+++++For%3A+Dec+31/26149331.html Thu, 12 Mar 2026 07:32:00 -0400 DTIL O.20406057 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PRECISION+BIOSCIENCES+++++For%3A+Mar+12/26149319.html si-local-file:///var/storage/secattach/20260312/26149319.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PRECISION+BIOSCIENCES+++++For%3A+Mar+12/26149319.html Thu, 12 Mar 2026 07:30:00 -0400 DTIL O.20406057 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PRECISION+BIOSCIENCES+++++For%3A+Mar+12/26149319.html si-local-file:///var/storage/secattach/20260312/26149319.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PRECISION+BIOSCIENCES+++++For%3A+Mar+12/26149319.html Thu, 12 Mar 2026 07:30:00 -0400 DTIL O.20406057 http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html <p class="bwalignc"> - <i>PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity </i><i>-</i> </p><p class="bwalignc"> - <i>Strong Phase 1 ELIMINATE-B trial execution for PBGENE-HBV with 13 patients now dosed across first 5 cohorts; Data updates expected at medical conferences throughout 2026 -</i> </p><p class="bwalignc"> - <i>Received IND Clearance for PBGENE-DMD enabling IRB and site activation for Phase 1/2 FUNCTION-DMD trial; Data from multiple patients expected by year-end 2026 -</i> </p><p class="bwalignc"> - <i>Raised $75 Million in November 2025 extending expected cash runway through multiple clinical inflection points between 2026 and the end of 2028 -</i> </p> <p> http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html Thu, 12 Mar 2026 07:00:00 -0400 A.01908724 A.06822034 A.06891908 A.13456177 A.25926438 A.50213784 A.60012011 DTIL O.00184548 O.00440398 O.01689677 O.08407916 O.13810818 O.20026344 O.20406057 O.20988509 O.41321359 TGTX http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html <p class="bwalignc"> - <i>PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity </i><i>-</i> </p><p class="bwalignc"> - <i>Strong Phase 1 ELIMINATE-B trial execution for PBGENE-HBV with 13 patients now dosed across first 5 cohorts; Data updates expected at medical conferences throughout 2026 -</i> </p><p class="bwalignc"> - <i>Received IND Clearance for PBGENE-DMD enabling IRB and site activation for Phase 1/2 FUNCTION-DMD trial; Data from multiple patients expected by year-end 2026 -</i> </p><p class="bwalignc"> - <i>Raised $75 Million in November 2025 extending expected cash runway through multiple clinical inflection points between 2026 and the end of 2028 -</i> </p> <p> http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html Thu, 12 Mar 2026 07:00:00 -0400 A.01908724 A.06822034 A.06891908 A.13456177 A.25926438 A.50213784 A.60012011 DTIL O.00184548 O.00440398 O.01689677 O.08407916 O.13810818 O.20026344 O.20406057 O.20988509 O.41321359 TGTX http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html <p class="bwalignc"> - <i>PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity </i><i>-</i> </p><p class="bwalignc"> - <i>Strong Phase 1 ELIMINATE-B trial execution for PBGENE-HBV with 13 patients now dosed across first 5 cohorts; Data updates expected at medical conferences throughout 2026 -</i> </p><p class="bwalignc"> - <i>Received IND Clearance for PBGENE-DMD enabling IRB and site activation for Phase 1/2 FUNCTION-DMD trial; Data from multiple patients expected by year-end 2026 -</i> </p><p class="bwalignc"> - <i>Raised $75 Million in November 2025 extending expected cash runway through multiple clinical inflection points between 2026 and the end of 2028 -</i> </p> <p> http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html Thu, 12 Mar 2026 07:00:00 -0400 A.01908724 A.06822034 A.06891908 A.13456177 A.25926438 A.50213784 A.60012011 DTIL O.00184548 O.00440398 O.01689677 O.08407916 O.13810818 O.20026344 O.20406057 O.20988509 O.41321359 TGTX http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html <p class="bwalignc"> - <i>PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity </i><i>-</i> </p><p class="bwalignc"> - <i>Strong Phase 1 ELIMINATE-B trial execution for PBGENE-HBV with 13 patients now dosed across first 5 cohorts; Data updates expected at medical conferences throughout 2026 -</i> </p><p class="bwalignc"> - <i>Received IND Clearance for PBGENE-DMD enabling IRB and site activation for Phase 1/2 FUNCTION-DMD trial; Data from multiple patients expected by year-end 2026 -</i> </p><p class="bwalignc"> - <i>Raised $75 Million in November 2025 extending expected cash runway through multiple clinical inflection points between 2026 and the end of 2028 -</i> </p> <p> http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html Thu, 12 Mar 2026 07:00:00 -0400 A.01908724 A.06822034 A.06891908 A.13456177 A.25926438 A.50213784 A.60012011 DTIL O.00184548 O.00440398 O.01689677 O.08407916 O.13810818 O.20026344 O.20406057 O.20988509 O.41321359 TGTX http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html <p class="bwalignc"> - <i>PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity </i><i>-</i> </p><p class="bwalignc"> - <i>Strong Phase 1 ELIMINATE-B trial execution for PBGENE-HBV with 13 patients now dosed across first 5 cohorts; Data updates expected at medical conferences throughout 2026 -</i> </p><p class="bwalignc"> - <i>Received IND Clearance for PBGENE-DMD enabling IRB and site activation for Phase 1/2 FUNCTION-DMD trial; Data from multiple patients expected by year-end 2026 -</i> </p><p class="bwalignc"> - <i>Raised $75 Million in November 2025 extending expected cash runway through multiple clinical inflection points between 2026 and the end of 2028 -</i> </p> <p> http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html Thu, 12 Mar 2026 07:00:00 -0400 A.01908724 A.06822034 A.06891908 A.13456177 A.25926438 A.50213784 A.60012011 DTIL O.00184548 O.00440398 O.01689677 O.08407916 O.13810818 O.20026344 O.20406057 O.20988509 O.41321359 TGTX http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html <p class="bwalignc"> - <i>PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity </i><i>-</i> </p><p class="bwalignc"> - <i>Strong Phase 1 ELIMINATE-B trial execution for PBGENE-HBV with 13 patients now dosed across first 5 cohorts; Data updates expected at medical conferences throughout 2026 -</i> </p><p class="bwalignc"> - <i>Received IND Clearance for PBGENE-DMD enabling IRB and site activation for Phase 1/2 FUNCTION-DMD trial; Data from multiple patients expected by year-end 2026 -</i> </p><p class="bwalignc"> - <i>Raised $75 Million in November 2025 extending expected cash runway through multiple clinical inflection points between 2026 and the end of 2028 -</i> </p> <p> http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html Thu, 12 Mar 2026 07:00:00 -0400 A.01908724 A.06822034 A.06891908 A.13456177 A.25926438 A.50213784 A.60012011 DTIL O.00184548 O.00440398 O.01689677 O.08407916 O.13810818 O.20026344 O.20406057 O.20988509 O.41321359 TGTX http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html <p class="bwalignc"> - <i>PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity </i><i>-</i> </p><p class="bwalignc"> - <i>Strong Phase 1 ELIMINATE-B trial execution for PBGENE-HBV with 13 patients now dosed across first 5 cohorts; Data updates expected at medical conferences throughout 2026 -</i> </p><p class="bwalignc"> - <i>Received IND Clearance for PBGENE-DMD enabling IRB and site activation for Phase 1/2 FUNCTION-DMD trial; Data from multiple patients expected by year-end 2026 -</i> </p><p class="bwalignc"> - <i>Raised $75 Million in November 2025 extending expected cash runway through multiple clinical inflection points between 2026 and the end of 2028 -</i> </p> <p> http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html Thu, 12 Mar 2026 07:00:00 -0400 A.01908724 A.06822034 A.06891908 A.13456177 A.25926438 A.50213784 A.60012011 DTIL O.00184548 O.00440398 O.01689677 O.08407916 O.13810818 O.20026344 O.20406057 O.20988509 O.41321359 TGTX http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html <p class="bwalignc"> - <i>PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity </i><i>-</i> </p><p class="bwalignc"> - <i>Strong Phase 1 ELIMINATE-B trial execution for PBGENE-HBV with 13 patients now dosed across first 5 cohorts; Data updates expected at medical conferences throughout 2026 -</i> </p><p class="bwalignc"> - <i>Received IND Clearance for PBGENE-DMD enabling IRB and site activation for Phase 1/2 FUNCTION-DMD trial; Data from multiple patients expected by year-end 2026 -</i> </p><p class="bwalignc"> - <i>Raised $75 Million in November 2025 extending expected cash runway through multiple clinical inflection points between 2026 and the end of 2028 -</i> </p> <p> http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html Thu, 12 Mar 2026 07:00:00 -0400 A.01908724 A.06822034 A.06891908 A.13456177 A.25926438 A.50213784 A.60012011 DTIL O.00184548 O.00440398 O.01689677 O.08407916 O.13810818 O.20026344 O.20406057 O.20988509 O.41321359 TGTX http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html <p class="bwalignc"> - <i>PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity </i><i>-</i> </p><p class="bwalignc"> - <i>Strong Phase 1 ELIMINATE-B trial execution for PBGENE-HBV with 13 patients now dosed across first 5 cohorts; Data updates expected at medical conferences throughout 2026 -</i> </p><p class="bwalignc"> - <i>Received IND Clearance for PBGENE-DMD enabling IRB and site activation for Phase 1/2 FUNCTION-DMD trial; Data from multiple patients expected by year-end 2026 -</i> </p><p class="bwalignc"> - <i>Raised $75 Million in November 2025 extending expected cash runway through multiple clinical inflection points between 2026 and the end of 2028 -</i> </p> <p> http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html Thu, 12 Mar 2026 07:00:00 -0400 A.01908724 A.06822034 A.06891908 A.13456177 A.25926438 A.50213784 A.60012011 DTIL O.00184548 O.00440398 O.01689677 O.08407916 O.13810818 O.20026344 O.20406057 O.20988509 O.41321359 TGTX http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html <p class="bwalignc"> - <i>PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity </i><i>-</i> </p><p class="bwalignc"> - <i>Strong Phase 1 ELIMINATE-B trial execution for PBGENE-HBV with 13 patients now dosed across first 5 cohorts; Data updates expected at medical conferences throughout 2026 -</i> </p><p class="bwalignc"> - <i>Received IND Clearance for PBGENE-DMD enabling IRB and site activation for Phase 1/2 FUNCTION-DMD trial; Data from multiple patients expected by year-end 2026 -</i> </p><p class="bwalignc"> - <i>Raised $75 Million in November 2025 extending expected cash runway through multiple clinical inflection points between 2026 and the end of 2028 -</i> </p> <p> http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html Thu, 12 Mar 2026 07:00:00 -0400 A.01908724 A.06822034 A.06891908 A.13456177 A.25926438 A.50213784 A.60012011 DTIL O.00184548 O.00440398 O.01689677 O.08407916 O.13810818 O.20026344 O.20406057 O.20988509 O.41321359 TGTX http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html <p class="bwalignc"> - <i>PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity </i><i>-</i> </p><p class="bwalignc"> - <i>Strong Phase 1 ELIMINATE-B trial execution for PBGENE-HBV with 13 patients now dosed across first 5 cohorts; Data updates expected at medical conferences throughout 2026 -</i> </p><p class="bwalignc"> - <i>Received IND Clearance for PBGENE-DMD enabling IRB and site activation for Phase 1/2 FUNCTION-DMD trial; Data from multiple patients expected by year-end 2026 -</i> </p><p class="bwalignc"> - <i>Raised $75 Million in November 2025 extending expected cash runway through multiple clinical inflection points between 2026 and the end of 2028 -</i> </p> <p> http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html Thu, 12 Mar 2026 07:00:00 -0400 A.01908724 A.06822034 A.06891908 A.13456177 A.25926438 A.50213784 A.60012011 DTIL O.00184548 O.00440398 O.01689677 O.08407916 O.13810818 O.20026344 O.20406057 O.20988509 O.41321359 TGTX http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html <p class="bwalignc"> - <i>PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity </i><i>-</i> </p><p class="bwalignc"> - <i>Strong Phase 1 ELIMINATE-B trial execution for PBGENE-HBV with 13 patients now dosed across first 5 cohorts; Data updates expected at medical conferences throughout 2026 -</i> </p><p class="bwalignc"> - <i>Received IND Clearance for PBGENE-DMD enabling IRB and site activation for Phase 1/2 FUNCTION-DMD trial; Data from multiple patients expected by year-end 2026 -</i> </p><p class="bwalignc"> - <i>Raised $75 Million in November 2025 extending expected cash runway through multiple clinical inflection points between 2026 and the end of 2028 -</i> </p> <p> http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html Thu, 12 Mar 2026 07:00:00 -0400 A.01908724 A.06822034 A.06891908 A.13456177 A.25926438 A.50213784 A.60012011 DTIL O.00184548 O.00440398 O.01689677 O.08407916 O.13810818 O.20026344 O.20406057 O.20988509 O.41321359 TGTX http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html <p class="bwalignc"> - <i>PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity </i><i>-</i> </p><p class="bwalignc"> - <i>Strong Phase 1 ELIMINATE-B trial execution for PBGENE-HBV with 13 patients now dosed across first 5 cohorts; Data updates expected at medical conferences throughout 2026 -</i> </p><p class="bwalignc"> - <i>Received IND Clearance for PBGENE-DMD enabling IRB and site activation for Phase 1/2 FUNCTION-DMD trial; Data from multiple patients expected by year-end 2026 -</i> </p><p class="bwalignc"> - <i>Raised $75 Million in November 2025 extending expected cash runway through multiple clinical inflection points between 2026 and the end of 2028 -</i> </p> <p> http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html Thu, 12 Mar 2026 07:00:00 -0400 A.01908724 A.06822034 A.06891908 A.13456177 A.25926438 A.50213784 A.60012011 DTIL O.00184548 O.00440398 O.01689677 O.08407916 O.13810818 O.20026344 O.20406057 O.20988509 O.41321359 TGTX http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html <p class="bwalignc"> - <i>PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity </i><i>-</i> </p><p class="bwalignc"> - <i>Strong Phase 1 ELIMINATE-B trial execution for PBGENE-HBV with 13 patients now dosed across first 5 cohorts; Data updates expected at medical conferences throughout 2026 -</i> </p><p class="bwalignc"> - <i>Received IND Clearance for PBGENE-DMD enabling IRB and site activation for Phase 1/2 FUNCTION-DMD trial; Data from multiple patients expected by year-end 2026 -</i> </p><p class="bwalignc"> - <i>Raised $75 Million in November 2025 extending expected cash runway through multiple clinical inflection points between 2026 and the end of 2028 -</i> </p> <p> http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html Thu, 12 Mar 2026 07:00:00 -0400 A.01908724 A.06822034 A.06891908 A.13456177 A.25926438 A.50213784 A.60012011 DTIL O.00184548 O.00440398 O.01689677 O.08407916 O.13810818 O.20026344 O.20406057 O.20988509 O.41321359 TGTX http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html <p class="bwalignc"> - <i>PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity </i><i>-</i> </p><p class="bwalignc"> - <i>Strong Phase 1 ELIMINATE-B trial execution for PBGENE-HBV with 13 patients now dosed across first 5 cohorts; Data updates expected at medical conferences throughout 2026 -</i> </p><p class="bwalignc"> - <i>Received IND Clearance for PBGENE-DMD enabling IRB and site activation for Phase 1/2 FUNCTION-DMD trial; Data from multiple patients expected by year-end 2026 -</i> </p><p class="bwalignc"> - <i>Raised $75 Million in November 2025 extending expected cash runway through multiple clinical inflection points between 2026 and the end of 2028 -</i> </p> <p> http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html Thu, 12 Mar 2026 07:00:00 -0400 A.01908724 A.06822034 A.06891908 A.13456177 A.25926438 A.50213784 A.60012011 DTIL O.00184548 O.00440398 O.01689677 O.08407916 O.13810818 O.20026344 O.20406057 O.20988509 O.41321359 TGTX http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html <p class="bwalignc"> - <i>PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity </i><i>-</i> </p><p class="bwalignc"> - <i>Strong Phase 1 ELIMINATE-B trial execution for PBGENE-HBV with 13 patients now dosed across first 5 cohorts; Data updates expected at medical conferences throughout 2026 -</i> </p><p class="bwalignc"> - <i>Received IND Clearance for PBGENE-DMD enabling IRB and site activation for Phase 1/2 FUNCTION-DMD trial; Data from multiple patients expected by year-end 2026 -</i> </p><p class="bwalignc"> - <i>Raised $75 Million in November 2025 extending expected cash runway through multiple clinical inflection points between 2026 and the end of 2028 -</i> </p> <p> http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html Thu, 12 Mar 2026 07:00:00 -0400 A.01908724 A.06822034 A.06891908 A.13456177 A.25926438 A.50213784 A.60012011 DTIL O.00184548 O.00440398 O.01689677 O.08407916 O.13810818 O.20026344 O.20406057 O.20988509 O.41321359 TGTX http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html <p class="bwalignc"> - <i>PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity </i><i>-</i> </p><p class="bwalignc"> - <i>Strong Phase 1 ELIMINATE-B trial execution for PBGENE-HBV with 13 patients now dosed across first 5 cohorts; Data updates expected at medical conferences throughout 2026 -</i> </p><p class="bwalignc"> - <i>Received IND Clearance for PBGENE-DMD enabling IRB and site activation for Phase 1/2 FUNCTION-DMD trial; Data from multiple patients expected by year-end 2026 -</i> </p><p class="bwalignc"> - <i>Raised $75 Million in November 2025 extending expected cash runway through multiple clinical inflection points between 2026 and the end of 2028 -</i> </p> <p> http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html Thu, 12 Mar 2026 07:00:00 -0400 A.01908724 A.06822034 A.06891908 A.13456177 A.25926438 A.50213784 A.60012011 DTIL O.00184548 O.00440398 O.01689677 O.08407916 O.13810818 O.20026344 O.20406057 O.20988509 O.41321359 TGTX http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html <p class="bwalignc"> - <i>PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity </i><i>-</i> </p><p class="bwalignc"> - <i>Strong Phase 1 ELIMINATE-B trial execution for PBGENE-HBV with 13 patients now dosed across first 5 cohorts; Data updates expected at medical conferences throughout 2026 -</i> </p><p class="bwalignc"> - <i>Received IND Clearance for PBGENE-DMD enabling IRB and site activation for Phase 1/2 FUNCTION-DMD trial; Data from multiple patients expected by year-end 2026 -</i> </p><p class="bwalignc"> - <i>Raised $75 Million in November 2025 extending expected cash runway through multiple clinical inflection points between 2026 and the end of 2028 -</i> </p> <p> http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html Thu, 12 Mar 2026 07:00:00 -0400 A.01908724 A.06822034 A.06891908 A.13456177 A.25926438 A.50213784 A.60012011 DTIL O.00184548 O.00440398 O.01689677 O.08407916 O.13810818 O.20026344 O.20406057 O.20988509 O.41321359 TGTX http://www.streetinsider.com/Business+Wire/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html <p class="bwalignc"> - <i>PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity </i><i>-</i> </p><p class="bwalignc"> - <i>Strong Phase 1 ELIMINATE-B trial execution for PBGENE-HBV with 13 patients now dosed across first 5 cohorts; Data updates expected at medical conferences throughout 2026 -</i> </p><p class="bwalignc"> - <i>Received IND Clearance for PBGENE-DMD enabling IRB and site activation for Phase 1/2 FUNCTION-DMD trial; Data from multiple patients expected by year-end 2026 -</i> </p><p class="bwalignc"> - <i>Raised $75 Million in November 2025 extending expected cash runway through multiple clinical inflection points between 2026 and the end of 2028 -</i> </p> <p> http://www.streetinsider.com/Business+Wire/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html Thu, 12 Mar 2026 07:00:00 -0400 A.01908724 A.06822034 A.06891908 A.13456177 A.25926438 A.50213784 A.60012011 DTIL O.00184548 O.00440398 O.01689677 O.08407916 O.13810818 O.20026344 O.20406057 O.20988509 O.41321359 TGTX http://www.streetinsider.com/Business+Wire/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html <p class="bwalignc"> - <i>PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity </i><i>-</i> </p><p class="bwalignc"> - <i>Strong Phase 1 ELIMINATE-B trial execution for PBGENE-HBV with 13 patients now dosed across first 5 cohorts; Data updates expected at medical conferences throughout 2026 -</i> </p><p class="bwalignc"> - <i>Received IND Clearance for PBGENE-DMD enabling IRB and site activation for Phase 1/2 FUNCTION-DMD trial; Data from multiple patients expected by year-end 2026 -</i> </p><p class="bwalignc"> - <i>Raised $75 Million in November 2025 extending expected cash runway through multiple clinical inflection points between 2026 and the end of 2028 -</i> </p> <p> http://www.streetinsider.com/Business+Wire/Precision+BioSciences+Reports+Fourth+Quarter+and+Fiscal+Year+2025+Financial+Results+and+Provides+Business+Update/26149112.html Thu, 12 Mar 2026 07:00:00 -0400 A.01908724 A.06822034 A.06891908 A.13456177 A.25926438 A.50213784 A.60012011 DTIL O.00184548 O.00440398 O.01689677 O.08407916 O.13810818 O.20026344 O.20406057 O.20988509 O.41321359 TGTX